Rafael Andrés Medina

Rafael Andrés Medina

Auto-generated profile, based on publicly available information

Rafael Andrés Medina

Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2011 in Nature Reviews Microbiology
Verified
Journal Article
Open access
PDF file
RMRafael A. Medina
Rafael A. Medina
AGAdolfo Garcia-Sastre
Adolfo Garcia-Sastre
Influenza A viruses are zoonotic viruses that can infect multiple hosts in nature, including birds, pigs, dogs, horses and humans. These viruses undergo substantial and constant reassortment in wild hosts, leading to the permanent possibility of the emergence of novel strains with epidemic or pandemic potential in humans. Human cases of infection with the highly pathogenic avian influenza virus carrying the H5 subtype of haemagglutinin (HA) and the N1 subtype of neuraminidinase (NA) (H5N1) continue to occur throughout parts of East and Southeast Asia, the Middle East, Africa and Europe. Outbreaks of H7 and H9 viruses in poultry and zoonotic infections of humans with these viral strains, as well as the emergence in 2009 of a pandemic H1N1 strain that originated in pigs, revealed the need and the value of systematic surveillance of susceptible hosts. Several viral adaptations are required for efficient infection, replication and transmission in a new host. In addition, several virus–host interactions modulate infection, and disease severity is a consequence of viral virulence determinants and host-specific responses to infection. Thus, the pathogenesis of influenza A viruses is multifactorial and host specific. The level of pre-existing immunity in the general population is a major determinant of pathogenesis. The emergence of antigenically novel viruses as a result of immune selection pressure leads to regular epidemics. In addition, the acquisition (through reassortment) of a novel HA subtype or an HA that is antigenically similar to older strains but to which a large proportion of the population is naive (as was the case with the 2009 pandemic H1N1 strain) can lead to the emergence of a pandemic virus. In humans, several underlying risk factors for infection have been identified. These include obesity, diabetes, cardiovascular disease, chronic lung disease (including asthma), pregnancy, old age, young age (<2 years) and being immunocompromised. Carefully designed clinical studies to elucidate the contribution of genetic susceptibility factors and polymorphisms, as well as to further define human susceptibility factors, are key for improving our understanding of the host determinants of influenza virus pathogenesis.

13 February 2017 in Nature Immunology
Verified
Journal Article
Open access
PDF file
RNRaffael Nachbagauer
Raffael Nachbagauer
ACAngela Choi
Angela Choi
AHAriana Hirsh
Ariana Hirsh
IMIrina Margine
Irina Margine
SISayaka Iida
Sayaka Iida
Florian KrammerFlorian Krammer
Florian Krammer
Antigenic drift and reassortment alters the epitopes of influenza virus. Krammer and colleagues reveal the cross-reactivity of antibody responses to viral hemagglutinin and neuraminidase in humans and several animal models, but the most prominent responses reflect ‘original antigenic sin’ to viral exposure. Infection with influenza virus induces antibodies to the viral surface glycoproteins hemagglutinin and neuraminidase, and these responses can be broadly protective. To assess the breadth and magnitude of antibody responses, we sequentially infected mice, guinea pigs and ferrets with divergent H1N1 or H3N2 subtypes of influenza virus. We measured antibody responses by ELISA of an extensive panel of recombinant glycoproteins representing the viral diversity in nature. Guinea pigs developed high titers of broadly cross-reactive antibodies; mice and ferrets exhibited narrower humoral responses. Then, we compared antibody responses after infection of humans with influenza virus H1N1 or H3N2 and found markedly broad responses and cogent evidence for 'original antigenic sin'. This work will inform the design of universal vaccines against influenza virus and can guide pandemic-preparedness efforts directed against emerging influenza viruses.

29 January 2010 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
Balaji ManicassamyBalaji Manicassamy
Balaji Manicassamy
RMRafael A Medina
Rafael A Medina
RHRong Hai
Rong Hai
TTTshidi Tsibane
Tshidi Tsibane
SSSilke Stertz
Silke Stertz
AGAdolfo Garcia-Sastre
Adolfo Garcia-Sastre
The recent 2009 pandemic H1N1 virus infection in humans has resulted in nearly 5,000 deaths worldwide. Early epidemiological findings indicated a low level of infection in the older population (>65 years) with the pandemic virus, and a greater susceptibility in people younger than 35 years of age, a phenomenon correlated with the presence of cross-reactive immunity in the older population. It is unclear what virus(es) might be responsible for this apparent cross-protection against the 2009 pandemic H1N1 virus. We describe a mouse lethal challenge model for the 2009 pandemic H1N1 strain, used together with a panel of inactivated H1N1 virus vaccines and hemagglutinin (HA) monoclonal antibodies to dissect the possible humoral antigenic determinants of pre-existing immunity against this virus in the human population. By hemagglutinination inhibition (HI) assays and vaccination/challenge studies, we demonstrate that the 2009 pandemic H1N1 virus is antigenically similar to human H1N1 viruses that circulated from 1918–1943 and to classical swine H1N1 viruses. Antibodies elicited against 1918-like or classical swine H1N1 vaccines completely protect C57B/6 mice from lethal challenge with the influenza A/Netherlands/602/2009 virus isolate. In contrast, contemporary H1N1 vaccines afforded only partial protection. Passive immunization with cross-reactive monoclonal antibodies (mAbs) raised against either 1918 or A/California/04/2009 HA proteins offered full protection from death. Analysis of mAb antibody escape mutants, generated by selection of 2009 H1N1 virus with these mAbs, indicate that antigenic site Sa is one of the conserved cross-protective epitopes. Our findings in mice agree with serological data showing high prevalence of 2009 H1N1 cross-reactive antibodies only in the older population, indicating that prior infection with 1918-like viruses or vaccination against the 1976 swine H1N1 virus in the USA are likely to provide protection against the 2009 pandemic H1N1 virus. This data provides a mechanistic basis for the protection seen in the older population, and emphasizes a rationale for including vaccination of the younger, naïve population. Our results also support the notion that pigs can act as an animal reservoir where influenza virus HAs become antigenically frozen for long periods of time, facilitating the generation of human pandemic viruses. Influenza A viruses generally infect individuals of all ages and cause severe respiratory disease in very young children and elderly people (>65 years). However, the 2009 pandemic H1N1 virus infection is predominantly seen in children and adults (<35 years of age), but rarely in people older than 65 years of age. Recent serological studies indicate that older people carry antibodies that recognize the 2009 H1N1 virus. This suggests that they may have been exposed to or vaccinated with an influenza virus similar to 2009 H1N1 virus. In this study, we wanted to identify the older H1N1 virus(es) that may confer protection to the elderly population. Using 11 different inactivated influenza A viruses that have circulated between 1918 to 2007, we immunized mice and challenged them with a lethal dose of the 2009 novel H1N1 virus. We find that mice vaccinated with human H1N1 viruses that circulated in 1918 and in 1943 were protected from the 2009 H1N1 virus. Also, the 1976 swine origin H1N1 virus, against which nearly 40 million people were immunized in 1976 in the United States, protects mice from death by the 2009 H1N1 virus. This indicates that people carrying antibodies against H1N1 viruses that circulated between 1918–1943 and to the 1976 swine origin H1N1 virus are likely to be protected against the 2009 pandemic H1N1. Importantly, our data underscores the significance of vaccinating people under 35 year of age, since the majority of them do not have protective antibodies against the 2009 H1N1, and provide a possible mechanism by which pandemic viruses could arise from antigenically frozen influenza viruses harbored in the swine population.

15 July 2010 in Journal of Virology
Verified
Journal Article
Open access
PDF file
BHBenjamin Hale
Benjamin Hale
JSJohn Steel
John Steel
RMRafael A. Medina
Rafael A. Medina
Balaji ManicassamyBalaji Manicassamy
Balaji Manicassamy
JYJianqiang Ye
Jianqiang Ye
AGAdolfo Garcia-Sastre
Adolfo Garcia-Sastre
In 2009, a novel swine-origin H1N1 influenza A virus emerged. Here, we characterize the multifunctional NS1 protein of this human pandemic virus in order to understand factors that may contribute to replication efficiency or pathogenicity. Although the 2009 H1N1 virus NS1 protein (2009/NS1) is an effective interferon antagonist, we found that this NS1 (unlike those of previous human-adapted influenza A viruses) is unable to block general host gene expression in human or swine cells. This property could be restored in 2009/NS1 by replacing R108, E125, and G189 with residues corresponding to human virus consensus. Mechanistically, these previously undescribed mutations acted by increasing binding of 2009/NS1 to the cellular pre-mRNA processing protein CPSF30. A recombinant 2009 H1N1 influenza A virus (A/California/04/09) expressing NS1 with these gain-of-function substitutions was more efficient than the wild type at antagonizing host innate immune responses in primary human epithelial cells. However, such mutations had no significant effect on virus replication in either human or swine tissue culture substrates. Surprisingly, in a mouse model of pathogenicity, the mutant virus appeared to cause less morbidity, and was cleared faster, than the wild type. The mutant virus also demonstrated reduced titers in the upper respiratory tracts of ferrets; however, contact and aerosol transmissibility of the virus was unaffected. Our data highlight a potential human adaptation of NS1 that seems absent in “classically derived” swine-origin influenza A viruses, including the 2009 H1N1 virus. We discuss the impact that a natural future gain of this NS1 function may have on the new pandemic virus in humans.

16 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
QZQian Zhang
Qian Zhang
MPMario Andrés Pizzorno
Mario Andrés Pizzorno
LMLisa Miorin
Lisa Miorin
PBPaul Bastard
Paul Bastard
AGAdrian Gervais
Adrian Gervais
JCJean-Laurent Casanova
Jean-Laurent Casanova
Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10−5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10−10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.

27 April 2022 in Science Translational Medicine
Verified
Journal Article
Open access
YBYannic C. Bartsch
Yannic C. Bartsch
XTXin Tong
Xin Tong
JKJaewon Kang
Jaewon Kang
MAMaría José Avendaño
María José Avendaño
ESEileen F. Serrano
Eileen F. Serrano
GAGalit Alter
Galit Alter
The Omicron variant of SARS-CoV-2 has been shown to evade neutralizing antibodies elicited by vaccination or infection. Despite the global spread of the Omicron variant, even among highly vaccinated populations, death rates have not increased concomitantly. These data suggest that immune mechanisms beyond antibody-mediated virus neutralization may protect against severe disease. In addition to neutralizing pathogens, antibodies contribute to control and clearance of infections through Fc effector mechanisms. Here, we probed the ability of vaccine-induced antibodies to drive Fc effector activity against the Omicron variant using samples from individuals receiving one of three SARS-CoV-2 vaccines. Despite a substantial loss of IgM, IgA, and IgG binding to the Omicron variant receptor binding domain (RBD) in samples from individuals receiving BNT162b2, mRNA-1273, and CoronaVac vaccines, stable binding was maintained against the full-length Omicron Spike protein. Compromised RBD binding IgG was accompanied by a loss of RBD-specific antibody Fcγ receptor (FcγR) binding in samples from individuals who received the CoronaVac vaccine, but RBD-specific FcγR2a and FcγR3a binding was preserved in recipients of mRNA vaccines. Conversely, Spike protein–specific antibodies exhibited persistent but reduced binding to FcγRs across all three vaccines, although higher binding was observed in samples from recipients of mRNA vaccines. This was associated with preservation of FcγR2a and FcγR3a binding antibodies and maintenance of Spike protein–specific antibody-dependent natural killer cell activation. Thus, despite the loss of Omicron neutralization, vaccine-induced Spike protein–specific antibodies continue to drive Fc effector functions, suggesting a capacity for extraneutralizing antibodies to contribute to disease control.